Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 26;24(6):1180.
doi: 10.3390/molecules24061180.

Oligonucleotide⁻Palladacycle Conjugates as Splice-Correcting Agents

Affiliations

Oligonucleotide⁻Palladacycle Conjugates as Splice-Correcting Agents

Madhuri Hande et al. Molecules. .

Abstract

2'-O-Methylribo phosphorothioate oligonucleotides incorporating cyclopalladated benzylamine conjugate groups at their 5'-termini have been prepared and their ability to hybridize with a designated target sequence was assessed by conventional UV melting experiments. The oligonucleotides were further examined in splice-switching experiments in human cervical cancer (HeLa Luc/705), human liver (HuH7_705), and human osteosarcoma (U-2 OS_705) reporter cell lines. Melting temperatures of duplexes formed by the modified oligonucleotides were approximately 5 °C lower than melting temperatures of the respective unmodified duplexes. The cyclopalladated oligonucleotides functioned as splice-correcting agents in the HeLa Luc/705 cell line somewhat more efficiently than their unmodified counterparts. Furthermore, the introduction of this chemical modification did not induce toxicity in cells. These results demonstrate the feasibility of using covalently metalated oligonucleotides as therapeutic agents.

Keywords: oligonucleotide; organometallic; palladacycle; palladium; splice-correction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
Cyclopalladation of oligonucleotides ON1b and ON2b. Reagents and conditions: (a) Li2PdCl4, MeCN, H2O, 25 °C, 24 h.
Figure 1
Figure 1
UV melting profiles for duplexes formed by the RNA ON3 (A) and DNA ON4 (B) targets with ON1a (cyan circles), ON1b (magenta triangles), and ON1b-Pd (yellow squares); pH = 7.4 (20 mM cacodylate buffer); [oligonucleotides] = 1.0 μM; I(NaClO4) = 0.10 M.
Figure 2
Figure 2
Restoration of Luciferase activity in HeLa Luc/705 cells by ON1a (cyan), ON1b (magenta), ON1b-Pd (yellow), ON2b (green), and ON2b-Pd (grey). The oligonucleotides were delivered by either lipofection (A) or gymnosis (B). Each column represents the mean with the standard error of the mean (SEM) of three (lipofection) or two (gymnosis) independent experiments (n ≥ 3). P-values were calculated by two-way ANOVA test and differences were statistically compared using post hoc Fisher’s LSD test (n.s. non-significant, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001).
Figure 3
Figure 3
Restoration of Luciferase activity in HuH7_705 (A,C) and U-2 OS_705 (B,D) cells by ON1a (cyan), ON1b (magenta), ON1b-Pd (yellow), ON2b (green), and ON2b-Pd (grey). The oligonucleotides were delivered by either lipofection (A,B) or gymnosis (C,D). Each column represents the mean with the standard error of the mean (SEM) of at least three independent experiments (n ≥ 3).
Figure 4
Figure 4
Viability of (A) HeLa Luc/705 and (B) HuH7_705 cells upon lipofection by oligonucleotides ON1a (cyan), ON1b (magenta), ON1b-Pd (yellow), and ON2b-Pd (grey). Each column represents the mean with the standard error of the mean (SEM) of two independent experiments (n = 2).

References

    1. Lundin K.E., Gissberg O., Smith C.I.E. Oligonucleotide Therapies: The Past and the Present. Hum. Gene Ther. 2015;26:475–485. doi: 10.1089/hum.2015.070. - DOI - PMC - PubMed
    1. Smith C.I.E., Zain R. Therapeutic Oligonucleotides: State of the Art. Annu. Rev. Pharmacol. Toxicol. 2019;59:605–630. doi: 10.1146/annurev-pharmtox-010818-021050. - DOI - PubMed
    1. Dias N., Stein C.A. Antisense Oligonucleotides: Basic Concepts and Mechanisms. Mol. Cancer Ther. 2002;1:347. - PubMed
    1. Gurav B., Srinivasan G. Antisense oligonucleotides as therapeutics and their delivery. Curr. Sci. 2017;112:490–498. doi: 10.18520/cs/v112/i03/490-498. - DOI
    1. Malik R., Roy I. Design and development of antisense drugs. Expert Opin. Drug Discov. 2008;3:1189–1207. doi: 10.1517/17460441.3.10.1189. - DOI - PubMed

MeSH terms

LinkOut - more resources